GRAIL $325 million private placement
The PIPE included common stock and pre-funded warrants
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Esperion Therapeutics follow-on offering
The shares are listed on Nasdaq
Turn Therapeutics direct listing
We advised Turn Therapeutics on its Nasdaq listing
Oruka Therapeutics $200 million at-the-market offering
We advised Oruka on the offering
Medtronic €1.5 billion notes offering
The investment-grade notes are due 2030 and 2045
MBX Biosciences $200 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Laekna HK$587 million placement of shares
We advised Laekna on the placement of new shares
Strive acquisition of Semler Scientific
We are advising Strive on the acquisition
Oruka Therapeutics $180 million private placement
The PIPE included common stock and pre-funded warrants
GenFleet Therapeutics HK$1.82 billion IPO
We advised GenFleet on its IPO and HKEX listing